Status:
UNKNOWN
Don't Treat Ghosts Anti-MRSA Antibiotics in Osteomyelitis Without Identified MRSA
Lead Sponsor:
Methodist Health System
Conditions:
Osteomyelitis
Eligibility:
All Genders
18-75 years
Brief Summary
Osteomyelitis is described as infection and inflammation of the long bone or bone marrow, often due to an open wound, operation, or invasive trauma.1 It is invasive and involves hematogenous seeding o...
Detailed Description
This disease can be classified by location of infection, extent of spread, chronicity, and source of infection.3,4 Osteomyelitis can be caused by a variety of organisms, most commonly gram-positive st...
Eligibility Criteria
Inclusion
- • Admission to any MHS hospital between April 1, 2017 and April 1, 2023
- \> 18 years of age
- Documented osteomyelitis location of the lower limb via ICD-10 code
- Documented imaging of lower limb osteomyelitis during index admission
- Planned intravenous (IV) antibiotics for at least 4 weeks
Exclusion
- • IV antibiotics for less than 24 hours inpatient
- Planned surgical intervention documented at admission
- Patients receiving monotherapy with an anti-MRSA agent
- Positive MRSA culture during index admission
- Current outpatient antibiotic use on index admission
- Repeated hospital admission during study period
Key Trial Info
Start Date :
June 23 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 23 2024
Estimated Enrollment :
365 Patients enrolled
Trial Details
Trial ID
NCT06096012
Start Date
June 23 2023
End Date
June 23 2024
Last Update
October 23 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Methodist Dallas Medical Center
Dallas, Texas, United States, 75203